恩华药业(002262) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥1,510,888,789.07, representing an increase of 11.29% compared to ¥1,357,565,651.12 in the same period last year[5] - Net profit attributable to shareholders was ¥300,705,740.93, up 13.35% from ¥265,282,248.03 year-on-year[5] - Basic and diluted earnings per share rose by 15.38% to ¥0.30 from ¥0.26 in the same period last year[5] - Net profit for the current period was ¥300,639,634.41, representing a 13.6% increase from ¥264,638,776.41 in the previous period[21] - Basic earnings per share for the current period were ¥0.30, up from ¥0.26 in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities increased by 36.69% to ¥319,272,299.47, compared to ¥233,582,275.30 in the previous year[5] - The company reported a significant increase in cash and cash equivalents, reaching CNY 2,082,237,101.86, up from CNY 1,416,389,329.18 at the beginning of the period, representing a growth of approximately 47%[16] - Cash inflow from investment activities amounted to ¥2,295,107,170.32, compared to ¥1,011,725,654.77, showing a significant increase of 126.67%[24] - Cash and cash equivalents at the end of the period totaled ¥1,926,390,521.55, an increase from ¥1,571,753,981.33, reflecting a growth of 22.56%[24] - Cash outflow from financing activities decreased to ¥12,398,245.97 from ¥18,049,004.82, a reduction of 31.56%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,869,023,396.87, a 5.08% increase from ¥8,440,005,655.95 at the end of the previous year[5] - The total liabilities increased to ¥1,276,276,509.68 from ¥1,166,489,878.17, reflecting a rise of 9.4%[18] - The company's equity attributable to shareholders rose to ¥7,619,618,940.41, compared to ¥7,300,321,724.48, an increase of 4.4%[18] Investment and Expenses - Research and development expenses increased by 33.88%, reflecting higher investment in R&D and stock incentive costs[12] - Investment income from financial products rose by 82.07%, attributed to increased short-term financial product returns[12] - Total operating costs amounted to ¥1,172,507,853.52, up from ¥1,036,808,322.12, reflecting a rise of 13.1%[20] - Cash paid for purchasing goods and services increased to ¥365,131,720.52 from ¥343,920,750.51, a rise of 6.67%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 33,514, with the largest shareholder holding 31.50% of the shares[11] - The major shareholders include Xu Zhou Enhua Investment Co., Ltd. holding 320,096,321 shares, representing a significant portion of the company’s equity[13] - The company’s actual controllers hold a combined 55.58% stake in Xu Zhou Enhua Investment Co., Ltd. and 16.42% in the company, ensuring substantial control[13] Other Financial Metrics - The company reported a decrease in financial expenses, with a net financial cost of -¥3,134,146.05, compared to -¥6,355,726.56 in the previous period[20] - Cash received from investment income rose to ¥18,089,170.32 from ¥6,725,654.77, an increase of 168.73%[24] - Cash received from tax refunds increased significantly to ¥346,253.96 from ¥19,865.69, a growth of 1647.73%[23] - The net increase in cash and cash equivalents was up 262.82%, driven by higher cash inflows from operating and investment activities[12]